Ladarixin, an inhibitor of the interleukin‐8 receptors <scp>CXCR1</scp> and <scp>CXCR2</scp> , in new‐onset type 1 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled trial

Abstract

In newly diagnosed patients with type 1 diabetes, short-term LDX treatment had no appreciable effect on preserving residual beta cell function.